You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 257 No. 15, April 17, 1987 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Brief Reports
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

National Adverse Drug Reaction Surveillance: 1985

Gerald A. Faich, MD, MPH; Deanne Knapp, PhD; Michael Dreis, RPh, MPH; Wayne Turner, PhD

JAMA. 1987;257(15):2068-2070.


Abstract

The Food and Drug Administration received about 37000 adverse drug reaction reports in 1985. Seventy-one percent of the reports involved toxic reactions to usual doses of drugs and were sent by medical care professionals directly to the Food and Drug Administration or to pharmaceutical manufacturers. In terms of severity, 2% of reports involved death while 21% involved hospitalization. The highest proportions of hospitalization or death were found for reports describing cardiovascular, hematologic, or respiratory effects. Nearly half of the reported deaths were in patients more than 59 years of age. The majority of reports described an adverse drug reaction occurring within two weeks of initial exposure to the suspected drug. Adverse drug reaction reporting by physicians is crucial to ensuring that pharmaceutical products are used appropriately.

(JAMA 1987;257:2068-2070)



Author Affiliations

From the Office of Epidemiology and Biostatistics, Center for Drugs and Biologics, Food and Drug Administration, Rockville, Md.


Footnotes

The opinions expressed are those of the authors and do not necessarily represent those of the Food and Drug Administration.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy
Salvo et al.
J Antimicrob Chemother 2007;60:121-126.
ABSTRACT | FULL TEXT  

Cutaneous Drug Reactions
Svensson et al.
Pharmacol. Rev. 2001;53:357-379.
ABSTRACT | FULL TEXT  

Dermatologic Adverse Drug Reactions in a Family Medicine Setting
Ives et al.
Arch Fam Med 1992;1:241-245.
ABSTRACT  

Cutaneous Adverse Reactions Associated With Calcium Channel Blockers
Stern and Khalsa
Arch Intern Med 1989;149:829-832.
ABSTRACT  

Adverse Drug Reactions and the Food and Drug Administration
Pearson and Kennedy
Journal of Pharmacy Practice 1989;2:209-213.
ABSTRACT  

Implementing a Hospital-Based Adverse Drug Reaction Reporting Program
Miwa
Journal of Pharmacy Practice 1989;2:214-220.
ABSTRACT  

A Statewide Program to Stimulate Reporting of Adverse Drug Reactions
Fincham
Journal of Pharmacy Practice 1989;2:239-244.
ABSTRACT  

Physician Knowledge, Attitudes, and Behavior Related to Reporting Adverse Drug Events
Rogers et al.
Arch Intern Med 1988;148:1596-1600.
ABSTRACT  

The Importance of Adverse Reaction Reporting by Physicians: Suprofen and the Flank Pain Syndrome
Rossi et al.
JAMA 1988;259:1203-1204.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.